Advisory board appointment advances protein degradation program

PhoreMost has added a heavyweight in drug discovery to its Scientific Advisory Board with the appointment of Dr Adam Gilbert, a long-standing leader in medicinal chemistry and targeted protein degradation.

Gilbert, who spent more than three decades at Pfizer, played central roles in the development of multiple breakthrough therapies, including the recently approved LITFULO™ (ritlecitinib) for alopecia areata, as well as contributions to the ABRYSVO™ RSV vaccine and the COMIRNATY® COVID-19 mRNA vaccine. His career has spanned covalent inhibitors, protein homeostasis modulators, and vaccine antigens - expertise that positions him to help shape PhoreMost’s growing degrader pipeline.

PhoreMost is building its discovery engine around the GlueSEEKER® platform, designed to identify molecular glues and other degrader molecules capable of addressing ‘undruggable’ targets in oncology and inflammation. Gilbert’s addition comes at a time when the degrader field is seeing growing validation and investment, with molecular glues increasingly viewed as one of the most promising therapeutic frontiers.

“Adam’s track record in turning complex science into market-ready therapeutics speaks for itself,” commented PhoreMost CSO, Dr Christian Dillon. “His perspective will be invaluable as we take our degrader programmes into clinical development.”

Gilbert himself noted the momentum in the space: “Molecular glues hold enormous potential to reshape drug discovery. PhoreMost’s approach to systematically uncovering these opportunities is exciting, and I look forward to helping translate that science into medicines with real patient impact.”

More information online